DSC127

DRUG2 trials

Sponsors

Integra LifeSciences Corporation

Conditions

Diabetic Foot Ulcers

Phase 3

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

TerminatedNCT01830348

Integra LifeSciences CorporationDiabetic Foot Ulcers

Start: 2013-02-28End: 2015-12-31Updated: 2017-12-12

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

TerminatedNCT01849965

Integra LifeSciences CorporationDiabetic Foot Ulcers

Start: 2013-04-30End: 2015-12-31Updated: 2017-12-12

Related Papers

NorLeu<sup>3</sup>-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers.

2015-06-0120 citations